Sitagliptin during pregnancy and lactation

Sitagliptin is generally not recommended during pregnancy due to limited data on its safety. However, if the benefits outweigh the risks, a healthcare provider may prescribe it.

Pregnancy   Category B ( FDA )

                      Category B3 ( TGA)

Sitagliptin is classified as Pregnancy Category B by the FDA and Category B3 by the Therapeutic Goods Administration (TGA) in Australia. This means animal reproduction studies have not shown any adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women. It's always essential to consult healthcare providers for personalized advice.

Use of Sitagliptin during lactation There is currently no data on the clinical use of sitagliptin during breastfeeding. Sitagliptin, with its shorter half-life compared to other dipeptidyl-peptidase IV inhibitors, could potentially be a preferable option among drugs in this class for nursing mothers. It's recommended to monitor the blood glucose levels of the breastfed infant while the mother is undergoing sitagliptin therapy. Nevertheless, considering an alternative medication might be advisable, particularly when nursing a newborn or preterm infant